Nissen, T. and Grosset, D.G. (2011) Benefits of L-dopa in the treatment of early Parkinson's disease. Focus on Parkinson's Disease, 22(1), 12-15-12-15.
Full text not currently available from Enlighten.
Publisher's URL: http://www.scopus.com/inward/record.url?eid=2-s2.0-79959808211&partnerID=MN8TOARS
Abstract
The introduction of levodopa (L-dopa) in the late 1960s revolutionized the management of Parkinson's disease (PD). Previously, the only class of medication available for its treatment was anticholinergic therapy. The discovery was highly significant, but controversial in its day regarding the central role of dopamine (rather than other neurotransmitters) in relation to the motor features of PD. Initially, reversal of akinesia in a catecholamine-depleted model was achieved by a mixture of D- and L-dopa. Subsequently, dopamine deficiency was shown at autopsy in the human striatum in 2 cases of PD, and reduced urine dopamine excretion was found in patients. Dopamine replacement therapy was introduced, initially using very high L-dopa doses before the discovery of dopamine decarboxylase inhibitors, which avoid peripheral degradation of L-dopa before passing the blood-brain barrier, and which - as carbidopa or benserazide - are now routinely used in combination with L-dopa.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Grosset, Professor Donald |
Authors: | Nissen, T., and Grosset, D.G. |
College/School: | College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience |
Journal Name: | Focus on Parkinson's Disease |
ISSN: | 0924-2015 |
University Staff: Request a correction | Enlighten Editors: Update this record